The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
PCV Chemotherapy for Recurrent Oligodendrogliomas and Oligoastrocytomas
Abstract
OBJECTIVE: The role of chemotherapy in the treatment of low-grade oligodendrogliomas and oligoastrocytomas is still unclear. A Phase II study was conducted to determine the benefits and toxicity of the procarbazine, lomustine, and vincristine (PCV) regimen in patients with low-grade oligodendrogliomas and oligoastrocytomas recurrent after surgery alone or surgery with radiotherapy. METHODS: Patients with both enhancing and nonenhancing tumors were treated with up to six cycles of standard PCV, and response was evaluated by conventional criteria based on computed tomography or magnetic resonance imaging. RESULTS: Sixteen of 26 patients (62%) responded to PCV: 3 (12%) experienced complete response, 13 (50%) experienced partial response, 8 (31%) had stable disease, and 2 (8%) had progressive disease. All symptomatic patients who responded and three with stable disease improved in seizure frequency, lateralizing signs, and symptoms of intracranial hypertension. The response rate for patients with enhancing lesions revealed by computed tomography or magnetic resonance imaging (74%) was significantly higher than that of patients with nonenhancing lesions (29%) (P < 0.05). Both oligodendrogliomas and oligoastrocytomas responded to PCV, with complete responses occurring in association with pure tumors only. The median time to tumor progression of all 26 patients was 24 months and was significantly longer for those with oligodendrogliomas compared with those with oligoastrocytomas (32 versus 12 mo) (P < 0.001). Chemotherapy was well tolerated, with mild hematological toxicity and rare skin rashes being the most frequent sequelae. CONCLUSION: These results suggest that chemotherapy with PCV is effective in the treatment of recurrent low-grade oligodendrogliomas and oligoastrocytomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Cited by
Primary brain tumours in adults
Ricard, D., Idbaih, A., Ducray, F., Lahutte, M., Hoang-Xuan, K., & Delattre, J.-Y. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61346-9 · Cited by 1,201
Primary brain tumours in adults
Behin, A., Hoang-Xuan, K., Carpentier, A. F., & Delattre, J.-Y. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12328-8 · Cited by 754
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Nabors, L. B., Portnow, J., Ahluwalia, M., Baehring, J., Brem, H., Brem, S., Butowski, N., Campian, J. L., Clark, S. W., Fabiano, A. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0052 · Cited by 539
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force
Soffietti, R., Baumert, B. G., Bello, L., Von Deimling, A., Duffau, H., Frénay, M., Grisold, W., Grant, R., Graus, F., Hoang‐Xuan, K., et al. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03151.x · Cited by 505
Self-citationGuillaume, D. J., Doolittle, N. D., Gahramanov, S., Hedrick, N. A., Delashaw, J. B., & Neuwelt, E. A. (2010) · PubMed · doi:10.1227/01.neu.0000363152.37594.f7 · Cited by 420
Metadata
- Authors
- Soffietti, R., Rudà, R., Bradac, G. B., & Schiffer, D.
- Venue
- Neurosurgery
- Published
- 1998-11
- Volume
- 43
- Issue
- 5
- Pages
- 1066-1073
- ISSN
- 0148-396X (ISSN-L)
- 1524-4040
- OpenAlex
- W1997964607
- Cited by
- 161
- References
- 1
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PCV Chemotherapy for Recurrent Oligodendrogliomas and Oligoastrocytomas. https://app.cochat.ai/papers/10.1097/00006123-199811000-00035
- The paper
- Soffietti, R., Rudà, R., Bradac, G. B., & Schiffer, D. (1998). PCV Chemotherapy for Recurrent Oligodendrogliomas and Oligoastrocytomas. Neurosurgery. https://doi.org/10.1097/00006123-199811000-00035
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.